GSK taps Omnicom's PHD as media agency of record

Share this article:

GlaxoSmithKline tapped Omnicom's PHD as media agency of record on all of its healthcare products, ousting incumbent WPP's MediaCom.

The Omnicom media agency will handle media planning and buying for OTC and prescription products with exception to Boniva, which GSK co-promotes with Genentech.

“PHD offered the most balance of strategic planning excellence and executional creativity and buying leverage to deliver efficiency and quality, and they're an innovator in the digital media space,” said a GSK spokesperson.

Advertising Age reported that Havas' MPG and Publicis' Starcom were also-rans in the review as well.

Separately, the company has just completed round two of an agency review for all of its US prescription drug advertising. The shortlist, such as it is, is comprised of 20 agencies, and a decision is expected on that early in the new year. Interpublic Group healthcare shops currently handle most of that business. 

Meanwhile, Pfizer announced it was retaining Aegis Group's Carat for media planning and buying following a review. "We are pleased to continue our nearly 11-year relationship with Carat as its agency of record for direct-to-consumer media planning and buying for the pharmaceutical business across all communications channels, and for TV and print buying for the over-the-counter consumer healthcare business in the US," said Ray Kerins, VP external affairs and worldwide communications at Pfizer. "This follows a routine review to ensure Pfizer retains the services that best fits the needs of its business."

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...